Thousand Oaks, California, September 3, 2025
News Summary
Amgen has announced a significant investment of $600 million to build a new research and development center in Thousand Oaks, California. Set to begin construction in the third quarter of this year, the facility aims to centralize the company’s bioscience efforts to foster collaboration among researchers. This initiative is part of Amgen’s broader strategy to strengthen domestic biomanufacturing and address supply chain challenges in the pharmaceutical industry, further indicating a rising demand for biotech innovation in the U.S.
California: Amgen Announces $600 Million Investment in New R&D Facility
Amgen, a leading biotechnology company, plans to invest $600 million to establish a new research and development center in Thousand Oaks, California. The project is set to break ground in the third quarter of this year and aims to centralize the company’s researchers, engineers, and scientists under one roof to enhance collaboration in drug discovery efforts.
Focus on Drug Discovery and Collaboration
The facility, while not intended for drug manufacturing, will provide advanced tools and an environment designed to inspire innovation and accelerate the process of scientific discovery. Amgen’s latest investment is part of a broader strategy to address challenges posed by U.S. import tariffs and supply chain pressures, enhancing domestic research and production capabilities.
Expanding Biotech Infrastructure
Amgen’s headquarters in Thousand Oaks occupies nearly 2 million square feet of biotech space in the Conejo Valley, approximately 40 miles west of Los Angeles. In 2025, major drugmakers are expected to announce over $270 billion in projects within the U.S., indicating a 185% increase in demand for biomanufacturing, according to commercial real estate firm JLL. Alexandria Real Estate Equities has also responded to the increasing demand by adding over half a million square feet of lab space in the first half of this year, further exemplifying a booming sector.
Recent Investments by Amgen and the Pharmaceutical Industry
In conjunction with the new R&D center, Amgen has previously declared a $900 million expansion of its manufacturing facility in Columbus, Ohio, and a separate $1 billion investment to build a second manufacturing site in Holly Springs, North Carolina. These investments coincide with a national trend as multiple pharmaceutical companies, including AstraZeneca, Eli Lilly, Sanofi, and Novartis, have made notable commitments to funding projects in the U.S.
Federal Support for Domestic Pharmaceutical Development
The Food and Drug Administration (FDA) has introduced initiatives aimed at streamlining the approval process for new drug manufacturing sites in the U.S., an effort that aligns with the White House’s goal to reduce construction timelines for pharmaceutical facilities, which can currently take a decade or more to complete. The Tax Cuts and Jobs Act of 2017 is cited as a key factor fostering these domestic investments, with expectations of new legislative supports enhancing future growth.
Amgen’s Commitment to Strengthening Supply Chains
Amgen’s CEO emphasized that the new investment would not only fortify U.S. drug supply chains but also bolster scientific research and innovation domestically. The company’s expansion reflects recent policies encouraging the reshoring of pharmaceutical production to address rising concerns about reliance on foreign sources in the healthcare sector.
FAQ
What is the purpose of the new Amgen facility in Thousand Oaks?
The new facility aims to centralize Amgen’s researchers, engineers, and scientists to enhance collaboration and advance drug discovery efforts.
How much is Amgen investing in this new facility?
Amgen is investing $600 million in the new research and development center.
When will construction begin?
Construction is expected to commence in the third quarter of this year.
Will the new facility be used for drug manufacturing?
No, the new facility will focus on research and development and will not function as a drug manufacturing site.
What recent trends are shaping investment in the pharmaceutical industry?
There has been a significant increase in investments in U.S. pharmaceutical projects, driven by greater demand for domestic biomanufacturing and recent federal regulatory reforms.
Key Features of Amgen’s New R&D Facility
| Feature | Description |
|---|---|
| Investment Amount | $600 million |
| Location | Thousand Oaks, California |
| Construction Start Date | Third Quarter of this Year |
| Focus | Research and Development |
| Not a Manufacturing Facility | Will not produce drugs; focus on scientific collaboration |
Deeper Dive: News & Info About This Topic
- Fierce Biotech: Amgen to Build $600M R&D Site
- Wikipedia: Amgen
- CNBC: Amgen’s Investment in R&D Facility
- Google Search: Amgen investment research facilities
- BioPharma Dive: Amgen’s New Center
- Encyclopedia Britannica: Biotechnology
- Business Facilities: Amgen Plans $600M Center
- Google Scholar: Amgen R&D investment
- FirstWord Pharma: Amgen’s Investment Update
- Google News: Amgen new R&D facility
Author: STAFF HERE BEVERLY HILLS WRITER
The Beverly Hills Staff Writer represents the experienced team at HEREBeverlyHills.com, your go-to source for actionable local news and information in Beverly Hills, Los Angeles County, and beyond. Specializing in "news you can use," we cover essential topics like product reviews for personal and business needs, local business directories, politics, real estate trends, neighborhood insights, and state news affecting the area—with deep expertise drawn from years of dedicated reporting and strong community input, including local press releases and business updates. We deliver top reporting on high-value events such as the Rodeo Drive Concours d'Elegance, the Beverly Hills artSHOW, Concerts on Canon, and holiday celebrations throughout the city. Our coverage extends to key organizations like the Beverly Hills Chamber of Commerce and Visit Beverly Hills, plus leading businesses in luxury fashion, hospitality, and entertainment that drive the local economy. As part of the broader HERE network, including HERELosAngeles.com, HERESantaAna.com, HEREHuntingtonBeach.com, and HERECostaMesa.com, we provide comprehensive, credible insights into Southern California's dynamic landscape.
